钙通道拮抗剂恬尔心在肾移植中的应用  

Application of the Calcium Antagonist Diltiazem in Kidney Transplantation

作　　者：郑克立[1] 王长希[1] 曾金云[1] 戴宇平[1] 丘小鹏 陈凌武[1] 陈立中[1] 

机构地区：[1]广州中山医科大学附一医院泌尿外科

出　　处：《中华器官移植杂志》1994年第4期154-155,共2页Chinese Journal of Organ Transplantation

摘　　要：供体取肾时，在肾灌注液中临时加入恬尔心针剂，受体自术日起长期口服恬尔心片剂，治疗６４例肾移植患者，同时与６４例对照组比较。结果表明，肾移植中应用恬尔心能减少急性肾小管坏死发生率和急性排斥发生率，并能提高环孢素Ａ（ＣｓＡ）的血浓度，减少其用量，并且对心血管及肝脏影响不大。s: 128 Patients with cadaveric kidney transplantation were divided into two groups, the Diltiazem (Dil) treated group (n=64) and the control group (n=64 ). In the Dil group, the kidneys were perfused with HC-A solution to which the calcium antagonist Dil was added; and Dil was administered orally to the graft recipients in this group for a long term. Compared with the contral group, the Dil group had significant advantages. The results indicated that the application of Dil in cadaveric kidney transplantation would lead to a reduction of the incidence of acute tubular necrosis, a decreased occurrence of acute rejection episodes and an increase in the CsA whole blood level which would lead to reduction of the CsA dose and have a finacial aspect to the patients. The results were also shown that Dil had little adverse effect on the cardiovascular and hepatic systems.

关 键 词：钙通道阻滞剂 恬尔心 肾移植 

分 类 号：R699.2[医药卫生—泌尿科学]